Marla Jalbut, M.D.
Investor / Seed/Early
Boston, US

About Marla
Dr. Marla Jalbut is an investor in Bessemer’s Boston office, where she focuses on biotech and healthcare investments.
In addition to her role at Bessemer, Marla serves as an attending physician in the Department of Medicine at Massachusetts General Hospital and is on the faculty at Harvard Medical School. She continues to see patients in the inpatient setting while teaching and mentoring medical trainees.
Before joining Bessemer, Marla was an investor at Omega Funds, a biotech-focused investment firm based in Boston. Her work spanned early-stage company creation to late clinical-stage biotech companies, and she served as a Board Observer at Aviceda Therapeutics, Ousia Pharma, and Rectify Pharma.
Marla earned an A.B. from Princeton University, an M.D. from Tufts University, and an M.B.A. from Harvard Business School. She completed her clinical training in internal medicine at Yale.
Outside of work, Marla enjoys spending time with friends and family, exploring new restaurants (she’s a retired food blogger), attending concerts, and cheering on the Baltimore Ravens.
Biotech
Healthcare
Latest News & Research
3 Total Posts
News
Boltz: building towards programmable molecular design
Bessemer Venture Partners leads Boltz's $110M Series A to back the team behind the state-of-the-art protein and small molecule foundation models for AI drug discovery.

Roadmap
Building biology-native data infrastructure for the AI era
As compute costs fall and models mature, sustaining a competitive edge in global drug development requires innovation across the entire data infrastructure stack. Biology-native data, agentic workflows, and lab automation will define the next generation of leading biotechs.

Article
State of Health AI 2026
Bessemer’s analysis explores how healthcare innovation is evolving beyond the hype, revealing the unique promise of Health Tech 2.0 through private market signals and the emerging power of the “Health AI X factor.”